<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.washingtontimes.com/news/2019/nov/24/novartis-to-buy-the-medicines-company-for-97-billi/"/>
    <meta property="og:site_name" content="The Washington Times"/>
    <meta property="article:published_time" content="2019-11-24T00:00:00+00:00"/>
    <meta property="og:title" content="Novartis to buy The Medicines Company for $9.7 billion"/>
    <meta property="og:description" content="Swiss pharmaceutical company Novartis has reached a deal to buy cholesterol drugmaker The Medicines Co. for $9.7 billion."/>
  </head>
  <body>
    <article>
      <h1>Novartis to buy The Medicines Company for $9.7 billion</h1>
      <address><time datetime="2019-11-24T00:00:00+00:00">24 Nov 2019</time> by <a rel="author">The Associated Press</a></address>
      <p>Swiss pharmaceutical company <a href="https://www.washingtontimes.com/topics/novartis/">Novartis</a> has reached a deal to buy cholesterol drugmaker The <a href="https://www.washingtontimes.com/topics/medicines-co/">Medicines Co.</a> for $9.7 billion.</p>
      <p><a href="https://www.washingtontimes.com/topics/novartis/">Novartis</a> will pay $85 per share for the New Jersey biotech company, a sharp increase over The <a href="https://www.washingtontimes.com/topics/medicine-co/">Medicine Co.</a>’s Friday closing price of $68.55 per share. The deal is worth $9.7 billion, including outstanding stock options and convertible debt.</p>
      <p>The <a href="https://www.washingtontimes.com/topics/medicines-co/">Medicines Co.</a> is in late-stage studies of a drug, inclisiran, meant to lower cholesterol.</p>
      <p><a href="https://www.washingtontimes.com/topics/novartis/">Novartis</a> has a pattern of acquiring other companies in recent years to expand its portfolio of drugs.</p>
      <p>“We’re hoping to reimagine treatment of the leading global cause of death. This could be a strong step forward in <a href="https://www.washingtontimes.com/topics/novartis/">Novartis</a>’ transformation into a focused <a href="https://www.washingtontimes.com/topics/the-medicines-co/">medicines company</a>,” <a href="https://www.washingtontimes.com/topics/novartis/">Novartis</a> CEO Vas Narasimhan tweeted Sunday.</p>
      <hr/>
      <hr/>
      <p>The <a href="https://www.washingtontimes.com/topics/medicines-co/">Medicines Co.</a> focuses on researching treatments for cardiovascular disease, specifically looking at ways to lower so-called bad cholesterol.</p>
      <anchor name="pagebreak">
        <p>The deal is expected to close early next year.</p>
        <h3>Sign up for Daily Newsletters</h3>
        <p>
          <a href="https://www.washingtontimes.com/newsletters/manage/">Manage Newsletters</a>
        </p>
        <p>Copyright © 2019 The Washington Times, LLC.</p>
        <h4>Please read our <a href="https://www.washingtontimes.com/comment-policy/">comment policy</a> before commenting.</h4>
        <p> </p>
      </anchor>
    </article>
  </body>
</html>